Now live: Pro — the full 13F research suite for serious investorsSee pricing →
Indaba Capital Management, L.P.

Q4 2023 · 13F-HR

Indaba Capital Management, L.P.holdings as filed

Filed 2024-02-14 · accession 0001011438-24-000257

$174.2M
Reported value
9
Positions
2023-12-31
Period end
View analyzed profile →PRO

Holdings as filed

CUSIPTickerIssuerValue% port.SharesClassVoting
34385PAF5STANDARD BIOTOOLS INC$43.4M24.9%40,500,000CommonSOLE
05988JAD5BAND 0.5 04/01/28BANDWIDTH INC$33.5M19.2%52,500,000CommonSOLE
68339B104ONTFON24 INC$33.4M19.2%4,240,256CommonSOLE
83303Y105SNAP ONE HOLDINGS CORP$27.7M15.9%3,109,281CommonSOLE
34385P108LABSTANDARD BIOTOOLS INC$16.5M9.45%7,446,229CommonSOLE
00430HAC6ACCELERATE DIAGNOSTICS INC$15.0M8.61%23,296,489CommonSOLE
590328209MACKEURMERRIMACK PHARMACEUTICALS IN$3.0M1.72%223,459CommonSOLE
69121K104OBDCBLUE OWL CAPITAL CORPORATION$1.4M0.78%92,568CommonSOLE
43538H111HLLY/WSHOLLEY INC$367,9710.21%669,159CommonSOLE

Source: SEC EDGAR · raw 13F holdings as filed. The Class column shows the option type when reported (Put/Call) or Common when the issuer's equity is held directly. 13F discloses long positions only.